Avoiding harm: Tackling problematic polypharmacy through strengthening expert generalist practice - PubMed (original) (raw)

Review

doi: 10.1111/bcp.14531. Epub 2020 Sep 9.

Affiliations

• PMID: 32840868
• DOI: 10.1111/bcp.14531

Free article

Review

Avoiding harm: Tackling problematic polypharmacy through strengthening expert generalist practice

Joanne Reeve. Br J Clin Pharmacol. 2021 Jan.

Free article

Abstract

Problematic polypharmacy is a growing challenge. Medication that is intended to improve patients' health and wellbeing is instead becoming part of the problem. The way we practice medicine has become a driver for the problem. Dealing with the challenge will need us to think differently about how we do clinical care. A 2013 Kings Fund report stated that tackling problematic polypharmacy requires us to actively build a principle of compromise into the way we use medicines. There are implications for how we consult and make decisions with patients, in how we design health practice and systems to support that decision making, and, in our understanding of the process of research, how we generate the knowledge that informs practice. This review considers the current state of play in all 3 areas and identifies some of the work we still need to do in order to generate the practice-based evidence needed to tackle this most challenging problem. Finding a way to redesign practice to address problematic polypharmacy could offer a template for tackling other related complex issues facing medical practice such as multimorbidity, chronic pain and complex mental health.

Keywords: generalism; multimorbidity; polypharmacy; problematic polypharmacy.

© 2020 The British Pharmacological Society.

PubMed Disclaimer

Similar articles

• Optimising a person-centred approach to stopping medicines in older people with multimorbidity and polypharmacy using the DExTruS framework: a realist review.
  Turk A, Wong G, Mahtani KR, Maden M, Hill R, Ranson E, Wallace E, Krska J, Mangin D, Byng R, Lasserson D, Reeve J. Turk A, et al. BMC Med. 2022 Aug 31;20(1):297. doi: 10.1186/s12916-022-02475-1. BMC Med. 2022. PMID: 36042454 Free PMC article. Review.
• Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensus.
  Muth C, Blom JW, Smith SM, Johnell K, Gonzalez-Gonzalez AI, Nguyen TS, Brueckle MS, Cesari M, Tinetti ME, Valderas JM. Muth C, et al. J Intern Med. 2019 Mar;285(3):272-288. doi: 10.1111/joim.12842. Epub 2018 Dec 10. J Intern Med. 2019. PMID: 30357955
• Person-centred medicines optimisation policy in England: an agenda for research on polypharmacy.
  Heaton J, Britten N, Krska J, Reeve J. Heaton J, et al. Prim Health Care Res Dev. 2017 Jan;18(1):24-34. doi: 10.1017/S1463423616000207. Epub 2016 Jun 16. Prim Health Care Res Dev. 2017. PMID: 27306579 Review.
• Health professional perspectives on the management of multimorbidity and polypharmacy for older patients in Australia.
  Mc Namara KP, Breken BD, Alzubaidi HT, Bell JS, Dunbar JA, Walker C, Hernan A. Mc Namara KP, et al. Age Ageing. 2017 Mar 1;46(2):291-299. doi: 10.1093/ageing/afw200. Age Ageing. 2017. PMID: 27836856
• Tackling Polypharmacy: A Multi-Source Decision Support System.
  Redeker G, Bowles J. Redeker G, et al. Stud Health Technol Inform. 2020 Jun 16;270:688-692. doi: 10.3233/SHTI200248. Stud Health Technol Inform. 2020. PMID: 32570471

Cited by

• When 'Best' Practice Isn't….
  Finn GM, Brown MEL. Finn GM, et al. Med Sci Educ. 2024 May 18;34(4):915-917. doi: 10.1007/s40670-024-02048-2. eCollection 2024 Aug. Med Sci Educ. 2024. PMID: 39099871 Free PMC article.
• Optimising a person-centred approach to stopping medicines in older people with multimorbidity and polypharmacy using the DExTruS framework: a realist review.
  Turk A, Wong G, Mahtani KR, Maden M, Hill R, Ranson E, Wallace E, Krska J, Mangin D, Byng R, Lasserson D, Reeve J. Turk A, et al. BMC Med. 2022 Aug 31;20(1):297. doi: 10.1186/s12916-022-02475-1. BMC Med. 2022. PMID: 36042454 Free PMC article. Review.
• Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis.
  Reeve J, Maden M, Hill R, Turk A, Mahtani K, Wong G, Lasserson D, Krska J, Mangin D, Byng R, Wallace E, Ranson E. Reeve J, et al. Health Technol Assess. 2022 Jul;26(32):1-148. doi: 10.3310/AAFO2475. Health Technol Assess. 2022. PMID: 35894932 Free PMC article. Review.

References

REFERENCES

1. 1. Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation. Making it safe and sound https://www.kingsfund.org.uk/sites/default/files/field/field_publication... (accessed 30 July 2020).
2. 1. EDeN: English Deprescribing Network Briefing. April 2019. https://www.sps.nhs.uk/articles/english-deprescribing-network-resource-p... (accessed 30 July 2020)
3. 1. Payne RA, Abel GA, Avery AJ, Mercer SW, Mo R. Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. Br J Clin Pharmacol. 2014;77(6):1073-1082.
4. 1. Krska J, Katusiime B, Corlett SA. Patient experiences of the burden of using medicines for long-term conditions and factors affecting burden: a cross-sectional survey. Health Soc Care Community. 2018;26(6):946-959.
5. 1. NHS England. Medicines Optimisation. https://www.england.nhs.uk/medicines-2/medicines-optimisation/ (accessed 6 June 2020)

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley